Previous studies have demonstrated that both gefitinib and erlotinib are markedly effective
for the treatment of non-small-cell lung cancer (NSCLC) with somatic activating mutations of …

Purpose To determine whether the addition of pemetrexed to gefitinib (P+ G) provides
clinical benefit, compared with gefitinib monotherapy, in patients with advanced …

Retrospective analysis has shown that activating mutations in exons 18–21 of the epidermal
growth factor receptor (EGFR) gene are a predictor of response to gefitinib. We conducted a …

Purpose This multicenter phase II study was undertaken to investigate the efficacy and
feasibility of gefitinib for patients with advanced non–small-cell lung cancer (NSCLC) …

Objective Although superior clinical benefits of epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitors (TKIs) in the treatment of advanced non-small-cell lung cancer …

Abstract Background: Exon 19 deletion (Del19) and exon 21 L858R substitution (L858R),
which account for 90% of epidermal growth factor receptor (EGFR) mutations as common …

Purpose Gefitinib is safe for the treatment of non-small cell lung cancer (NSCLC), but some
patients experience toxicities and require dose reduction. The purpose of this study was to …

Initial studies with the first-generation epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors gefitinib and erlotinib in patients with non-small cell lung cancer (NSCLC) …

Objective To compare the efficacy of the erlotinib versus gefitinib in the first-line treatment of
patients with advanced EGFR mutation-positive NSCLC. Methods Fifty patients with …

Background Chemotherapy is a partially effective treatment for advanced non-small-cell
lung cancer (NSCLC), the leading cause of cancer mortality in the US. The epidermal …